Amedeo Ferdinando Capetti, Maria Vittoria Cossu, Gaetana Sterrantino, Giorgio Barbarini, Simona Di Giambenedetto, Giuseppe Vittorio De Socio, GianCarlo Orofino, Antonio Di Biagio, Benedetto M Celesia, Stefano Rusconi, Barbara Argenteri, Giuliano Rizzardini
BACKGROUND: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients. OBJECTIVE: The primary objective is to report the 96-week virological suppression in our cohort, assessing the durability of this strategy in complicated situations. The secondary objective is to describe the safety and metabolic profile. METHODS: All patients who had switched to DTG plus RPV between October 1, 2014, and September 30, 2015, were analyzed using a retrospective-prospective design, approved by ethics committees...
February 1, 2018: Annals of Pharmacotherapy